The estimated Net Worth of Saira Ramasastry is at least $992 ezer dollars as of 11 June 2024. Ms. Ramasastry owns over 4,000 units of Vir Biotechnology Inc stock worth over $114,467 and over the last 12 years she sold VIR stock worth over $323,829. In addition, she makes $553,663 as Independent Director at Vir Biotechnology Inc.
Sign up
Ms. Ramasastry VIR stock SEC Form 4 insiders trading
Saira has made over 13 trades of the Vir Biotechnology Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 4,000 units of VIR stock worth $43,800 on 11 June 2024.
The largest trade she's ever made was exercising 10,000 units of Vir Biotechnology Inc stock on 19 May 2021 worth over $127,600. On average, Saira trades about 1,784 units every 75 days since 2012. As of 11 June 2024 she still owns at least 14,619 units of Vir Biotechnology Inc stock.
You can see the complete history of Ms. Ramasastry stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Saira Ramasastry biography
Saira Ramasastry serves as Independent Director of the Company. Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC since April 2009, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the board of directors of the following public companies: Sangamo Therapeutics Inc., Cassava Sciences, Inc., Innovate Biopharmaceuticals, Inc., and Glenmark Pharmaceuticals, Ltd. Ms. Ramasastry will step down from the board of directors of Innovate Biopharmaceuticals, Inc. in connection with its proposed merger with RDD Pharma Ltd., which is expected to close early in the second quarter of 2020.
What is the salary of Saira Ramasastry?
As the Independent Director of Vir Biotechnology Inc, the total compensation of Saira Ramasastry at Vir Biotechnology Inc is $553,663. There are 12 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.
How old is Saira Ramasastry?
Saira Ramasastry is 44, she's been the Independent Director of Vir Biotechnology Inc since 2019. There are 22 older and 1 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
What's Saira Ramasastry's mailing address?
Saira's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Insiders trading at Vir Biotechnology Inc
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I... és Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
What does Vir Biotechnology Inc do?
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
What does Vir Biotechnology Inc's logo look like?
Complete history of Ms. Ramasastry stock trades at Sangamo Therapeutics Inc, Mirum Pharmaceuticals Inc, Vir Biotechnology Inc, Cassava Sciences Inc, 9 Meters Biopharma és Akouos
Vir Biotechnology Inc executives and stock owners
Vir Biotechnology Inc executives and other stock owners filed with the SEC include:
-
George Scangos,
President, Chief Executive Officer, Director -
Howard Horn,
Chief Financial Officer, Secretary -
Herbert Virgin,
Executive Vice President of Research and Chief Scientific Officer -
Vicki Sato,
Independent Chairman of the Board -
Dr. Herbert W. Virgin IV, M.D., Ph.D.,
Exec. VP of Research & Chief Scientific Officer -
Dr. Herbert W. Virgin IV,
Exec. VP of Research & Chief Scientific Officer -
Dr. George A. Scangos Ph.D.,
Pres, CEO & Director -
Dr. Ann M. Hanly Ph.D.,
Exec. VP & Chief Technology Officer -
Phil Pang,
Chief Medical Officer -
Dr. George A. Scangos,
Pres, CEO & Director -
Dr. Phillip Pang M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Steven J. Rice,
Chief Admin. Officer -
Saira Ramasastry,
Independent Director -
Robert Perez,
Independent Director -
Phillip Sharp,
Independent Director -
Dr. Klaus Frueh,
Co-Founder & Scientific Advisor -
Robert More,
Independent Director -
Dipchand Nishar,
Independent Director -
Robert Nelsen,
Independent Director -
Elliott Sigal,
Independent Director -
Janet Napolitano,
Director -
Michael Kamarck,
Chief Technology Officer -
Jay Parrish,
Chief Business Officer -
Johanna Friedl-Naderer,
Exec. VP & COO -
Irene Pleasure J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Heather Rowe Armstrong,
VP of Investor Relations -
Dr. Aine M. Hanly Ph.D.,
Chief Technology Officer -
Dr. Louis J. Picker M.D.,
Co-Founder & Scientific Advisor -
Dr. Klaus Frueh Ph.D.,
Co-Founder & Scientific Advisor -
Dr. Neera Dahiya Ravindran M.D., MBA,
VP and Head of Investor Relations & Strategic Communications -
Dr. Louis J. Picker,
Co-Founder & Scientific Advisor -
Dr. Lawrence Corey,
Co-Founder & Scientific Advisor -
Permanent Fund Corp Alaska,
-
& Melinda Gates Foundation ...,
-
Johanna Friedl Naderer,
EVP & Chief Operating Officer -
Steven J. Rice,
Chief Administrative Officer -
Venture Partners Ix, Llcarc...,
-
Endurance (Cayman) Ltd Sb I...,
-
Dhabi Investment Authority ...,
-
Holdings (Private) Ltd Full...,
-
Program Ii (Co Invest Holdi...,
-
Mark Eisner,
EVP and Chief Medical Officer -
Klaus Frueh,
Director -
Venture Partners Ix, Llcarc...,
-
Kristina Burow,
Director -
Jeffrey S. Hatfield,
Director -
Norbert W Bischofberger,
Director -
Ramy Farid,
Director -
Sung Lee,
EVP & Chief Financial Officer -
Ann M. Hanly,
EVP & Chief Technology Officer -
Backer Marianne De,
Chief Executive Officer